Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial.
Rauck RL, Bookbinder SA, Bunker TR, Alftine CD, Ghalie R, Negro-Vilar A, de Jong E, Gershon S. Rauck RL, et al. J Opioid Manag. 2006 Nov-Dec;2(6):325-8, 331-3. doi: 10.5055/jom.2006.0048. J Opioid Manag. 2006. PMID: 17326594 Clinical Trial.
The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
Rauck RL, Bookbinder SA, Bunker TR, Alftine CD, Ghalie R, Negro-Vilar A, de Jong E, Gershon S. Rauck RL, et al. J Opioid Manag. 2006 May-Jun;2(3):155-66. doi: 10.5055/jom.2006.0025. J Opioid Manag. 2006. PMID: 17319449 Clinical Trial.
A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial.
Rauck RL, Bookbinder SA, Bunker TR, Alftine CD, Gershon S, de Jong E, Negro-Vilar A, Ghalie R. Rauck RL, et al. J Opioid Manag. 2007 Jan-Feb;3(1):35-43. doi: 10.5055/jom.2007.0037. J Opioid Manag. 2007. PMID: 17367093 Clinical Trial.
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. Blumenschein GR Jr, et al. Among authors: negro vilar a. J Clin Oncol. 2008 Apr 10;26(11):1879-85. doi: 10.1200/JCO.2007.12.2689. J Clin Oncol. 2008. PMID: 18398153 Clinical Trial.
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE. Ramlau R, et al. Among authors: negro vilar a. J Clin Oncol. 2008 Apr 10;26(11):1886-92. doi: 10.1200/JCO.2007.12.2614. J Clin Oncol. 2008. PMID: 18398154 Clinical Trial.
New progestins and potential actions.
Negro-Vilar A. Negro-Vilar A. J Soc Gynecol Investig. 2000 Jan-Feb;7(1 Suppl):S53-4. doi: 10.1016/s1071-5576(99)00056-8. J Soc Gynecol Investig. 2000. PMID: 10732331 Review.
211 results